Menu
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
1800 Bridge Pkwy
Redwood City, California 94065-1164
Phone: 16502510005
www.nevro.com
https://www.investing.com/news/pro/nevro-corp-pt-raised-to-45-at-truist-securities-following-meetings-with-cfo-rod-macleod-432SI-2948128
In last trading session, Nevro Corp. (NYSE:NVRO) saw 1.82 million shares changing hands with its beta currently measuring 0.77. Company’s recent per share price level of $41.69 trading at $4.99 or 13.60% at ring of the bell on the day assigns it a market valuation of $1.40B. That closing price of NVRO’s stock is at … Analysts Say That Nevro Corp. (NYSE:NVRO) Is Likely To Make It To $75.00 In 12 Months Read More »
Nevro Corporation (NYSE:NYSE:NVRO) Q3 2022 Earnings Conference Call November 02, 2022, 16:30 ET Company Participants Julie Dewey - Chief Corporate Communications & IR Officer Keith…
The following slide deck was published by Nevro Corp.
Nevro Corp Earnings, Revenue Beat in Q3
REDWOOD CITY, Calif., Nov. 2, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2022, narrowed its full-year 2022 guidance and…
The share price of Nevro Corp. (NYSE:NVRO) fell to $38.34 per share on Monday from $38.84. While Nevro Corp. has underperformed by -1.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -66.29%, with highs and lows ranging from $117.57 to $34.70, whereas the […]
Nevro Corp. (NVRO), a company focused on neuromodulation solutions, dropped at the open on Wednesday after its rival Boston Scientific (BSX) said that its Q3 sales for the pain…
https://www.investing.com/news/pro/nevro-corp-pt-lowered-to-43-at-truist-securities-432SI-2913772
In last trading session, Nevro Corp. (NYSE:NVRO) saw 0.79 million shares changing hands with its beta currently measuring 0.83. Company’s recent per share price level of $38.63 trading at $0.37 or 0.97% at ring of the bell on the day assigns it a market valuation of $1.54B. That closing price of NVRO’s stock is at … Nevro Corp. (NYSE:NVRO) Shares Are Up 10.17% From The Lows, But Can They Stay Up? Read More »
The U.S. Food and Drug Administration ((FDA)) approved Nevro''s (NVRO) Senza HFX iQ spinal cord stimulation ((SCS)) system
Healthcare equipment maker Nevro Corp. (NVRO) announced Monday that the recent decision by UnitedHealthcare (UNH) to limit coverage for spinal cord stimulation ((SCS)) devices is…
A share of Nevro Corp. (NYSE:NVRO) closed at $43.51 per share on Thursday, down from $49.13 day before. While Nevro Corp. has underperformed by -11.44%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -63.22%, with highs and lows ranging from $121.78 to $39.41, […]
https://www.investing.com/news/pro/united-healths-policy-change-a-drag-on-nevros-underlying-business--truist-securities-432SI-2906697
Nevro Corp. (NVRO) is down 8% in Thursday afternoon trading after UnitedHealth issued a new medical coverage determination for spinal cord stimulators that excludes coverage in some cases.
Company to Host Conference Call on Wednesday, November 2, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Oct. 5, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic…
Medical device company Nevro (NVRO) on Tuesday said the U.S. FDA had approved its manufacturing operations in Costa Rica
REDWOOD CITY, Calif., Oct. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that the U.S. Food and Drug Administration (FDA) has approved its…
SmartSet is a torque-limiting coupling with controlled slip based on the same technology as SafeSet, with the additional ability to also slip without releasing, to reduce the short duration and dynamic torque peaks without interrupting production. The SmartSet principle is simple: controlled slip torque for process improvement. The SmartSet coupling can safely slip up to […]